Law Offices of Howard G. Smith Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions Against FUTU, HUBG, PODD, and PLAB

Regulation
โดย GlobeNewswire·Read original
Summary · why it matters

The Law Offices of Howard G. Smith reminds investors that securities fraud class action lawsuits have been filed against Futu Holdings Limited, Hub Group, Inc., Insulet Corporation, and Photronics, Inc., with lead plaintiff deadlines ranging from August 25 to September 4, 2026. The complaint against Futu alleges the company made false or misleading statements by failing to disclose non-compliance with CSRC requirements, including conducting securities, public fund sales, and futures business in mainland China without proper licenses, which could lead to regulatory penalties and overstated financial results. Hub Group is accused of material misstatements in financial statements from Q1 2023 to Q3 2025 due to premature transaction recognition and understated costs. Insulet allegedly had defective manufacturing controls that created a risk of safety violations, while Photronics is said to have concealed severe bottlenecks in its high-end chip design release pipeline. Investors who suffered losses may contact the firm to discuss their legal rights.

Impact on stocks 4

Financials · 1 stocks
Futu Holdings Ltd
FUTU
▼ NegativeRegulationrelevance

Futu Holdings is alleged to have failed to disclose non-compliance with CSRC requirements, including conducting unlicensed securities, public fund sales, and futures business in mainland China, leading to a securities fraud class action.

Industrials · 1 stocks
Hub Group Inc
HUBG
▼ NegativeRegulationrelevance

Hub Group is accused of material misstatements in financial statements due to premature transaction recognition and understated costs, leading to a securities fraud class action.

Semiconductors · 1 stocks
Photronics Inc
PLAB
▼ NegativeRegulationrelevance

Photronics is alleged to have concealed severe bottlenecks in its high-end chip design release pipeline, resulting in a securities fraud class action.

Biotech & Genomic Medicine · 1 stocks
Insulet Corporation
PODD
▼ NegativeRegulationrelevance

Insulet is accused of having defective manufacturing controls that created a risk of safety violations, leading to a securities fraud class action.